A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Seviteronel (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Innocrin Pharmaceuticals
- 20 Sep 2017 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 20 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated